India Drug Makers Eye 10% Of Production Costs On Counterfeit Prevention
This article was originally published in PharmAsia News
Major Indian drug makers, including Elder Pharmaceuticals, Glenmark Pharmaceuticals, Lupin, Ranbaxy Laboratories and Unichem Laboratories spend as much as 10% of their generic production costs on preventing counterfeits.
You may also be interested in...
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.
Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.
Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.